Naureen Quibria
Stock Analyst at Capital One
(0)
# 5163
Out of 5,358 analysts
15
Total ratings
11.11%
Success rate
-43.43%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMEA Biomea Fusion | Initiates Coverage On: Overweight | 25 | 2.5 | 900% | 1 | Aug 29, 2024 | |
IMMP Immutep | Initiates Coverage On: Overweight | 10 | 1.88 | 431.91% | 1 | May 17, 2024 | |
ERAS Erasca | Initiates Coverage On: Overweight | 8 | 1.6 | 400% | 1 | Mar 11, 2024 | |
CARM CARISMA Therapeutics | Initiates Coverage On: Overweight | 10 | 0.19 | 5163.16% | 1 | Oct 3, 2023 | |
IMCR Immunocore Hldgs | Initiates Coverage On: Overweight | 84 | 37.26 | 125.44% | 1 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 7.17 | 457.88% | 1 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 11 | 8.38 | 31.26% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | n/a | n/a | 2 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 21 | 4 | 425% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | n/a | n/a | 1 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 900 | 5.59 | 16000.18% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Mar 16, 2021 |